Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

470.72 -6.38 (-1.34%)
Official Closing Price Updated: 4:15 PM EDT, Aug 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
75 76 Next >
News headline image
Vertex Pharmaceuticals (NASDAQ:VRTX) Beats Q2 CY2026 Sales Expectations, Full-Year Outlook Slightly Exceeds Expectations
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) announced better-than-expected revenue in Q2 CY2026, with sales up 12.5% year on year to $3.33 billion. ... 
Via StockStory
News headline image
Vertex Reports Second Quarter 2026 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Pharmaceuticals (VRTX) Q2 Earnings Report Preview: What To Look For
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results this Monday after the bell. Here’s what to look for. Vertex Pharmaceuticals be... 
Via StockStory
Topics Artificial Intelligence
News headline image
Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target ↗
There are other reasons to pay attention to Viking Therapeutics. 
Via The Motley Fool
Vertex Pharmaceuticals (NASDAQ:VRTX): Strong Growth and Textbooks Technical Setup for Breakout ↗
Via Chartmill
Vertex Pharmaceuticals (NASDAQ:VRTX): An Affordable Growth Stock Balancing Strong Fundamentals With Reasonable Valuation ↗
Via Chartmill
News headline image
Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy? ↗
The next six months may be decisive for the biotech. 
Via The Motley Fool
News headline image
AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions
From AbCellera Biologics Inc.
Via Business Wire
News headline image
3 Healthcare Stocks with Competitive Advantages
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme... 
Via StockStory
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TriCo Bancshares (Nasdaq – TCBK), Twin Vee PowerCats Co. (Nasdaq -VEEE), Crinetics Pharmaceuticals, Inc. (Nasdaq – CRNX), Element Solutions Inc. (NYSE – ESI)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Vertex Pharmaceuticals Just Made a $10 Billion Acquisition Worth Watching ↗
The biotech's diversification efforts continue. 
Via The Motley Fool
Topics Intellectual Property
News headline image
1 Nasdaq 100 Stock to Keep an Eye On and 2 We Question
The Nasdaq 100 (^NDX) is home to some of the biggest success stories in tech and growth investing. However, certain stocks in the index face challenges like ... 
Via StockStory
News headline image
$1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today ↗
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 7.55% on an annualized basis producing an average annual return of 19.41%. Currently, Vertex Pharmaceuticals... 
Via Benzinga
News headline image
Here's Why Vertex Was Willing to Pay a Premium of More Than 100% for Crinetics Pharmaceuticals ↗
Vertex's $10 billion acquisition may have spooked investors, given how rich it appeared to be. 
Via The Motley Fool
News headline image
Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy? ↗
Vertex Pharmaceuticals recently announced its largest-ever acquisition. 
Via The Motley Fool
News headline image
Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse ↗
Vertex Pharmaceuticals (NASDAQ:VRTX) said it has entered into a definitive agreement to acquire Crinetics Pharmaceuticals for $85 per share in cash, a transaction Vertex executives described as a... 
Via MarketBeat
News headline image
Is This Biotech Stock a Buy Near Its 52-Week High? ↗
It's been a volatile year for the company, but don't let that scare you away. 
Via The Motley Fool
News headline image
Why This Pharmaceutical Stock Jumped Close to 100% This Week ↗
It is getting acquired by a larger firm in the sector. 
Via The Motley Fool
Topics Bonds
News headline image
3 Reasons to Buy CRISPR Therapeutics Stock ↗
The company's innovative qualities may pay rich dividends down the road. 
Via The Motley Fool
News headline image
Vertex Pharmaceuticals Just Made a $10 Billion Move. Is the Stock a Buy? ↗
Additional blockbuster drugs may be on the horizon. 
Via The Motley Fool
Topics Intellectual Property
News headline image
1 Momentum Stock to Research Further and 2 Facing Headwinds
Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such a... 
Via StockStory
News headline image
Vertex’s Crinetics Deal Balances Growth with Integration Risk ↗
Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for $10 billion at $85 per share, adding the approved drug PALSONIFY and pipeline candidate Atumelant to expand beyond its cystic fibrosis... 
Via MarketBeat
News headline image
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics ↗
This new technology could one day significantly expand the market for gene-editing biotechs. 
Via The Motley Fool
News headline image
Vertex Is Paying a 102% Premium to Acquire Crinetics for $10 Billion. Here's Whether the Deal Is Worth It. ↗
This buy gives Vertex both a recently-commercialized drug, and a very strong lead candidate. 
Via The Motley Fool
News headline image
Vertex Is Buying Crinetics for $10 Billion. Here's What Investors Need to Know. ↗
The drugmaker is paying up for a new growth engine. Is the price disciplined? 
Via The Motley Fool
Topics Intellectual Property
News headline image
Vertex to Announce Second Quarter 2026 Financial Results on August 3rd
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
3 Cash-Heavy Stocks with Promising Prospects
In a world where many businesses have shaky balance sheets, some have ignored the crowd and exercised prudence. These cash-heavy companies shine bright for t... 
Via StockStory
Which S&P500 stocks are showing activity after the closing bell on Monday? ↗
Via Chartmill
News headline image
Vertex to Acquire Crinetics Pharmaceuticals
From Vertex Pharmaceuticals Incorporated and Crinetics Pharmaceuticals, Inc.
Via Business Wire
News headline image
Vertex Pharmaceuticals Stock Is Soaring and at a New All-Time High. Could It Still Be Heading Even Higher? ↗
The pharma stock is up around 17% this year. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
75 76 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.